TRUE NORTH COPPER LIMITED (ASX:TNC) Releases Quarterly Cash Flow Report
TRUE NORTH COPPER LIMITED (ASX:TNC) releases quarterly cash flow report, detailing financial activities and 18-month funding for exploration programs.
Tag: Investor Relations
Beacon Minerals (ASX:BCN) Reports 31% Increase in Q4 Gold Production
Beacon Minerals (ASX:BCN) reports a 31% increase in Q4 gold production, exceeding forecasts and enhancing its financial stability.
Wide Open Agriculture (ASX:WOA) Releases Q4 2024 Quarterly Report
Wide Open Agriculture (ASX:WOA) reports Q4 2024 results, highlighting new product development, significant cost reductions, and strategic expansion into South East Asia.
Rapid Lithium Limited (ASX:RLL) Announces Q4 Activities
Rapid Lithium Limited (ASX:RLL) completes Midwest acquisition, launches $2M capital raise, and updates on strategic projects.
Papyrus Australia Ltd (ASX:PPY) Releases Q4 2024 Cash Flow Report
Papyrus Australia Ltd (ASX:PPY) reports its Q4 2024 cash flow, detailing operational outflows and future funding strategies.
Papyrus Australia Ltd (ASX:PPY) Announces Quarterly Activity Report
Papyrus Australia Ltd (ASX:PPY) reports Q4 activities including a Vietnam joint venture, new board members, and significant financial achievements.
Aspire Limited (ASX:AKM) Advances OCCP Development and Strengthens Financial Position
Aspire Limited (ASX:AKM) reports significant progress in its Ovoot Coking Coal Project and maintains a strong financial position in the December 2024 quarter.
ReNu Energy (ASX:RNE) Announces Q4 2024 Activities and Strategic Transactions
ReNu Energy (ASX:RNE) reports Q4 2024 activities, including a management buyout proposal, asset sales, and financial updates.
HITIQ Limited (ASX:HIQ) Converts $1.6m Notes to Shares and Secures New Advisory Mandate
HITIQ Limited (ASX:HIQ) converts $1.6m in notes into shares and secures a new advisory mandate to enhance US investor relations.
Chimeric Therapeutics Limited (ASX:CHM) Reports Q4 Activities
Chimeric Therapeutics (ASX:CHM) advances clinical trials, secures $5M in funding, and appoints Dr Rebecca McQualter as CEO in Q4 report.